Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Leukemia & lymphoma/Leukemia and lymphomaOpen Access

Flow cytometric and molecular MRD in AML: current methods, clinical applications and challenges

View Full Paper
Ask AI
Bookmark
Share

Authors

LHLukas H. HaaksmaJCJacqueline CloosDLDavid C. de Leeuw

Discussion

Loading...

Member takes

Overview

Review reveals prognostic value of measurable residual disease in AML treatment, highlighting new methodologies and clinical applications.

Key Points

  • Measurable residual disease improves prognostic information in acute myeloid leukemia management.
  • Methods like flow cytometry and next-generation sequencing enhance treatment strategies for AML patients.
  • Clinical applications of MRD support decision-making in stem cell transplantation and treatment intensity.
  • Standardization of MRD methods is crucial for enhancing accuracy and reliability across laboratories.

Cite This Study

Haaksma et al. (2025) studied this question.

synapsesocial.com/papers/68c242e0b210217d647a4853https://doi.org/10.1080/10428194.2025.2547993
View Full Paper
Ask AI
Bookmark
Share